Arcturus Therapeutics (ARCT) Reports Q4 Loss of $1.03

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($1.03). Revenue for the quarter came in at $7.2 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Boeing wins $121 million Navy contract for P-8A upgrades
• Edgewell stock surges on report of rejected takeover bid